Genenta Science SpA logo

Genenta Science SpANASDAQ: GNTA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Italy

IPO:

15 December 2021

Website:

http://www.genenta.com

Next earnings report:

30 August 2024

Last dividends:

N/A

Next dividends:

N/A

Market cap

$56.47 M
-73%vs. 3y high
36%vs. sector

PE ratio

-
-vs. 3y high
-vs. sector

PB ratio

2.50
-83%vs. 3y high
64%vs. sector

PS ratio

-
-vs. 3y high
-vs. sector

Price

regular market | Fri, 28 Jun 2024 13:30:00 GMT
$3.10-$0.01(-0.32%)

Dividend

No data over the past 3 years

EPS diluted

EPS diluted target

--
No data over the past 3 years

Revenue

Revenue target

--
No data over the past 3 years

Revenue

Net income

--
No data over the past 3 years

Analysts recommendations

Total assets

Total liabilities

$24.70 M$2.12 M

Institutional Ownership

Included in screeners

Small cap companies
Worst performing stocks today
Stocks with price below SMA 200
Stocks with low beta

Similar companies

Enzo Biochem logo

Enzo Biochem (ENZ)

CollPlant Biotechnologies logo

CollPlant Biotechnologies (CLGN)

Alpha Teknova logo

Alpha Teknova (TKNO)

ARCA biopharma logo

ARCA biopharma (ABIO)

Rallybio logo

Rallybio (RLYB)

Cidara Therapeutics logo

Cidara Therapeutics (CDTX)

Neuronetics logo

Neuronetics (STIM)

Rockwell Medical logo

Rockwell Medical (RMTI)

GNTA Latest News

Genenta to Present at Upcoming Scientific and Investor Conferences
GlobeNewsWire06 September 2023 Sentiment: POSITIVE

MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells towards a permanent self-vaccination against cancer, will present at several upcoming scientific and investor conferences.

What type of business is Genenta Science SpA?

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

What sector is Genenta Science SpA in?

Genenta Science SpA is in the Healthcare sector

What industry is Genenta Science SpA in?

Genenta Science SpA is in the Biotechnology industry

What country is Genenta Science SpA from?

Genenta Science SpA is headquartered in Italy

When did Genenta Science SpA go public?

Genenta Science SpA initial public offering (IPO) was on 15 December 2021

What is Genenta Science SpA website?

https://www.genenta.com

Is Genenta Science SpA in the S&P 500?

No, Genenta Science SpA is not included in the S&P 500 index

Is Genenta Science SpA in the NASDAQ 100?

No, Genenta Science SpA is not included in the NASDAQ 100 index

Is Genenta Science SpA in the Dow Jones?

No, Genenta Science SpA is not included in the Dow Jones index

When does Genenta Science SpA report earnings?

The next expected earnings date for Genenta Science SpA is 30 August 2024